Ovarian Cancers

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in the part of the gene that is central to BRCA2 function, according to study results.

The FDA approved a new liquid formulation of thiotepa for the treatment of with adenocarcinoma of the breast or ovary, according to the agent’s manufacturer.

The V Foundation has awarded Debattama Sen, PhD, a $200,000 grant to explore strategies to regulate T-cell dysfunction in chronic viral infection and tumors in patients with cancer.

A study conducted at University of Pennsylvania’s Abramson Cancer Center has revealed possible drivers of recurrence in breast and ovarian tumors with BRCA1/BRCA2 mutations.